Dr. Ting Xu has more than 20 years of experience in the research and development of innovative biologics. He held positions as chief researcher and project leader with Archemix, Serono and Biogen, where he was involved in the development of numerous now approved and launched drugs in US and Europe.
Dr. Xu returned to China in 2008 to found biopharmaceutical companies such as Suzhou Alphamab and Alphamab Oncology. In 2019, Dr Xu successfully led Alphamab Oncology to Initial Public Listing on the Main Board of the Hong Kong Stock Exchange (stock code: 9966 HK).
In the early days of his return to China, Dr. Xu focused development of biosimilars and innovative biologics in fields such as cancer, autoimmunity, infertility, and coagulation. The number of the biosimilars in portfolio rank the first in China. Through collaboration cooperation with other pharmaceutical companies, several products have been approved for commercialization, such as bevacizumab (QILU Pharmaceutical) or Recombinant Factor VIII (CTTQ) and Recombinant FSH (Livzon). As one of the earlier returnees, Dr. Xu made significant contribution to the leap-forward development of China’s biopharmaceutical industry.
Dr. Xu led the R&D of 16 innovative biologics in the company, most of that will enter the markets in near future. He has created a number of protein and antibody engineering technology platforms with proprietary intellectual property rights; Dr. Xu successfully developed the world's first anti-PD-(L)1 subcutaneous drug (KN035) with single domain antibody and took a leading role in developing bispecific antibodies in China; He is one of the most prolific scientists in exploring bispecifics in China. Currently Dr. Xu is leading the research on multi-dimensional antibody modification technologies, aiming to develop the next generation of multifunctional large molecule drugs with better precision, lower toxicity, and superior therapeutic efficacy.
Dr. Xu holds a B.S. in Biochemistry from Nanjing University and a Ph.D. from the Chinese Academy of Science. Currently, Dr. Xu holds adjunct professorship in the Shanghai Institute of Materia Medica, the Chinese Academy of Sciences, Nanjing University and Southeast University. He has led 5 national-level projects such as the "Major New Drug Development" special project. He is author and co-author of more than 20 academic papers in high impact journals and the inventor of more than 100 patents.
Ms. Yang Liu has over 10 years of experience in the biotech industry in USA, researching and developing antibody drug conjugates designed to disrupt the progression of cancer. Prior to Alphamab Oncology, she served as Vice President of Corporate Operations at Dingfu Biotarget, a biotech company focused on Immuno-Oncology. She also served as a physician before.
Currently, Ms. Liu is responsible for corporate operations including human resources, supply chain, engineering and information technology. She is an executive director on the board.
Mr. Xu has been our director since November 2018. Mr. Xu currently serves as a managing director of PAG Growth Capital, an affiliate of PAG (formerly known as Pacific Alliance Group), where Mr. Xu has been a member since September 2011. During his time at PAG, Mr. Xu has led various successful investments, including a number of investments in the healthcare sector such as Rongchang Pharmaceuticals and Sinopharm Rosino. Prior to PAG, Mr. Xu held various positions at Morgan Stanley, TPG Capital and Apax Partners.
Mr. Xu obtained his master’s degree in management science and engineering from Stanford University, and bachelor’s degree in electronic information engineering from Zhejiang University.
Dr. GUO Zijian, has been serving as a professor of School of Chemistry and Chemical Engineering of Nanjing University since May 1999. From October 1996 to April 1999, he was a research associate at the University of Edinburgh in the United Kingdom. Dr. Guo was granted the Outstanding Achievement Award by Asian Society of Biological Inorganic Chemistry, Luigi Sacconi Medal from the Italian Chemical Society, the First Prize of China’s State Natural Science Award.
Dr. Guo received his doctor degree from the University of Padova in Italy and worked as a postdoctoral research fellow at Birkbeck College of the University of London in the United Kingdom.
Mr. Wei Kevin Cheng is a managing partner of a corporate finance advisory firm, with over 29 years of experiences in audit, financial management and board corporate governance at publicly listed companies. Mr. Wei previously served as CFO for Solarfun Power Holdings and IFM Investment Limited, both were publicly listed companies in U.S.
Mr. Wei currently serves as the chairman of the board, an independent non-executive director and the chairman of audit committee of Tibet Water Resources Ltd. (stock code: 1115); an independent non-executive director and the chairman of audit and compliance committee of Nexteer Automotive Group Limited (stock code: 1316), both are listed on the Hong Kong Stock Exchange.
Mr. Wei graduated with a bachelor’s degree with a double major in accounting and business administration from Central Washington University in the U.S. He is a member of the American Institute of Certified Public Accountants.
Mr. Dong Wu is a venture partner at 6 Dimensions Capital. Mr. Wu worked for Johnson & Johnson for over 10 years and served different positions including the head of Asia Pacific Innovation Center, a vice president of global engineering and emerging market research and development, the Emerging Market Innovation Centre Leader, a vice president of Research Development & Engineering, Asia Pacific and a senior director of emerging market research and development. Mr. Wu is currently the founder and an executive director of Shanghai Jiuben Technology Co., Ltd.
Mr. Wu received his bachelor’s degree in applied chemistry from Fudan University and an executive Master of Business Administration from China-Europe International Business School.
